Compare Banco Santander SA (SAN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs TG Therapeutics Inc — how do they compare? Banco Santander SA trades at $13.5 (market cap $192.86B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Banco Santander SA is far larger — about 23.6× TG Therapeutics Inc's market cap, and Banco Santander SA pays a 2.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and TG Therapeutics Inc for 16 Days on average.
| SAN | TGTX | |
|---|---|---|
Market Cap | $192.86B | $8.16B |
Volume | 10,644,519 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $15.05 | $59.06 |
52-Week Low | $9.65 | $26.94 |
Typical Hold Time | 55 Days | 16 Days |
Enterprise Value | $360.86B | $8.37B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.49, down 1.24% with bearish technical signals, though fundamentals show strength with 26.25% net margins and 16.07% ROE. Recent earnings show mixed quarterly performance, beating in Q1 but missing in Q2. The company completed the Webster Bank acquisition in August 2026, expanding U.S. presence and driving record profits. Cash flow trends remain negative, but revenue and net income have grown steadily from 2022-2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings supporting growth potential from strategic acquisitions and digital transformation. Key risks include negative cash flow trends, high debt levels at $288B, and economic sensitivity. The stock offers value at 13.55 P/E but requires monitoring of operational cash flow recovery and integration of recent acquisitions.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
